Mathias Vrolix

Showing 1-17 of 17 articles

Coronary interventions

Ticagrelor alone or conventional dual antiplatelet therapy in patients with stable or acute coronary syndromes

Franzone A, McFadden E, Leonardi S, Piccolo R, Vranckx P, Serruys P, Hamm C, Steg P, Heg D, Branca M, Jüni P, Windecker S, Valgimigli M, Benit E, Janssens L, Ferrario M, Zurakowski A, Diletti R, Dominici M, Huber K, Slagboom T, Buszman P, Bolognese L, Tumscitz C, Bryniarski K, Aminian A, Vrolix M, Petrov I, Garg S, Naber C, Prokopczuk J, Liebetrau C

June 2, 2020 | 10.4244/EIJ-D-20-00145

Coronary interventions

Twelve-month outcomes of 400 patients treated with a resorbable metal scaffold: insights from the BIOSOLVE-IV registry

Verheye S, Wlodarczak A, Montorsi P, Bennett J, Torzewski J, Haude M, Vrolix M, Buck T, Aminian A, van der Schaaf R, Nuruddin A, Lee M

February 7, 2020 | 10.4244/EIJ-D-18-01058

Coronary interventions

Validation of the updated logistic clinical SYNTAX score for all-cause mortality in the GLOBAL LEADERS trial

Chichareon P, Onuma Y, van Klaveren D, Modolo R, Kogame N, Takahashi K, Chang C, Tomaniak M, Asano T, Katagiri Y, van Geuns R, Bolognese L, Tumscitz C, Vrolix M, Petrov I, Garg S, Naber C, Sabate M, Iqbal J, Wykrzykowska J, Piek J, Spitzer E, Jüni P, Hamm C, Steg P, Valgimigli M, Vranckx P, Windecker S, Serruys P

August 9, 2019 | 10.4244/EIJ-D-19-00184

Functional comparison between the BuMA Supreme biodegradable polymer sirolimus-eluting stent and a durable polymer zotarolimus-eluting coronary stent using quantitative flow ratio: PIONEER QFR substudy

Asano T, Katagiri Y, Collet C, Tenekecioglu E, Miyazaki Y, Sotomi Y, Amoroso G, Aminian A, Brugaletta S, Vrolix M, Hernandez-Antolin R, van de Harst P, Iñiguez A, Janssens L, Smits P, Wykrzykowska J, Ribeiro V, Pereira H, da Silva P, Piek J, Reiber J, von Birgelen C, Sabate M, Onuma Y, Serruys P

August 3, 2018 | 10.4244/EIJ-D-17-00461

First-in-man randomised comparison of the BuMA Supreme biodegradable polymer sirolimus-eluting stent versus a durable polymer zotarolimus-eluting coronary stent: the PIONEER trial

von Birgelen C, Asano T, Amoroso G, Aminian A, Brugaletta S, Vrolix M, Hernández-Antolín R, van de Harst P, Iñiguez A, Janssens L, Smits P, Wykrzykowska J, Ribeiro V, Pereira H, da Silva P, Piek J, Onuma Y, Serruys P, Sabate M

April 20, 2018 | 10.4244/EIJ-D-17-00462

Stable CAD

Long-term clinical outcomes of a crystalline sirolimus-eluting coronary stent with a fully bioabsorbable polymer coating: five-year outcomes from the DESSOLVE I and II trials

Wijns W, Vrolix M, Verheye S, Schoors D, Slagboom T, Gosselink M, Benit E, Kandzar D, Donohoe D, Ormiston J

April 6, 2018 | 10.4244/EIJ-D-17-00230

Coronary interventions

Impact of gender difference in hospital outcomes following percutaneous coronary intervention. Results of the Belgian Working Group on Interventional Cardiology (BWGIC) registry

Lempereur M, Magne J, Cornelis K, Hanet C, Taeymans Y, Vrolix M, Legrand V

June 10, 2016 | 10.4244/EIJY14M12_11

Coronary interventions

COmplex coronary Bifurcation lesions: RAndomized comparison of a strategy using a dedicated self-expanding biolimus-eluting stent versus a culotte strategy using everolimus-eluting stents: primary results of the COBRA trial

Dubois C, Bennett J, Dens J, De Cock D, Desmet W, Belmans A, Ughi G, Sinnaeve P, Vrolix M, D’hooge J, Adrianssens T

April 20, 2016 | 10.4244/EIJY15M05_02

Coronary interventions

STENTYS Self-Apposing® sirolimus-eluting stent in ST-segment elevation myocardial infarction: results from the randomised APPOSITION IV trial

van Geuns R, Yetgin T, La Manna A, Tamburino C, Souteyrand G, Motreff P, Koch K, Vrolix M, IJsselmuiden A, Amoroso G, Berland J, Montalescot G, Teiger E, Christiansen E, Spaargaren R, Wijns W

February 12, 2016 | 10.4244/EIJV11I11A248

Incidence and potential mechanism of resolved, persistent and newly acquired malapposition three days after implantation of self-expanding or balloon-expandable stents in a STEMI population: insights from optical coherence tomography in the APPOSITION II study

Nakatani S, Onuma Y, Ishibashi Y, Karanasos A, Regar E, Garcia-Garcia H, Tamburino C, Fajadet J, Vrolix M, Witzenbichler B, Eeckhout E, Spaulding C, Reczuch K, La Manna A, Spaargaren R, Capodanno D, van Langenhove G, Verheye S, Serruys P, van Geuns R

December 20, 2015 | 10.4244/EIJY15M11_01

A first-in-man clinical evaluation of Ultimaster, a new drug-eluting coronary stent system: CENTURY study

Barbato E, Salinger-Martinovic S, Sagic D, Beleslin B, Vrolix M, Neskovic A, Jagic N, Verheye S, Mehmedbegovic Z, Wijns W

September 22, 2015 | 10.4244/EIJY14M08_06

Uninterrupted oral anticoagulation versus bridging in patients with long-term oral anticoagulation during percutaneous coronary intervention: subgroup analysis from the WOEST trial

Dewilde W, Janssen P, Kelder J, Verheugt F, de Smet B, Adrianssens T, Vrolix M, Brueren G, Vandendriessche T, Van Mieghem C, Cornelis K, Vos J, Breet N, ten Berg J

August 20, 2015 | 10.4244/EIJY14M06_07

Randomised study of a bioabsorbable polymer-coated sirolimus-eluting stent: results of the DESSOLVE II trial

Wijns W, Vrolix M, Verheye S, Schoors D, Slagboom T, Gosselink M, Benit E, Donohoe D, Knape C, Attizzani G, Lansky A, Ormiston J

April 20, 2015 | 10.4244/EIJY14M05_03

Optical coherence tomography study of healing characteristics of paclitaxel-eluting balloons vs. everolimus-eluting stents for in-stent restenosis: the SEDUCE (Safety and Efficacy of a Drug elUting balloon in Coronary artery rEstenosis) randomised clinical trial

Adrianssens T, Dens J, Ughi G, Bennett J, Dubois C, Sinnaeve P, Wiyono S, Coosemans M, Belmans A, D’hooge J, Vrolix M, Desmet W

August 19, 2014 | 10.4244/EIJV10I4A77

Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial

Legrand V, Cuisset T, Chenu P, Vrolix M, Martinez C, Dens J, Gach O, Boland J, Claeys M, Magne J, Barbato E, Wijns W

June 20, 2014 | 10.4244/EIJV10I2A34

Optical coherence tomography (OCT) in PCI for in-stent restenosis (ISR): rationale and design of the SEDUCE (Safety and Efficacy of a Drug elUting balloon in Coronary artery rEstenosis) study

Adrianssens T, Dens J, Ughi G, Coosemans M, Onsea K, Dubois C, Sinnaeve P, Vrolix M, Desmet W

May 17, 2011

One-year results of coronary revascularization in diabetic patients with multivessel coronary artery disease.

Macaya C, Garcia-Garcia H, Colombo A, Morice M, Legrand V, Kuck K, Sheiban I, Suttorp MJ, Carrié D, Vrolix M, Wittebols K, Stoll H-P, Donohoe D, Bressers M, Serruys P

May 20, 2006

Latest news

NEW ISSUE

CTOs, next-day discharge after TAVI, ViV, cerebral embolic protection, TMVR

August 7, 2020

NEW

Ahead of Print: Coronary Artery Thrombosis in COVID-19

August 7, 2020

Editorial

Coronary collaterals, the natural grafts of CTO lesions

C. Di Mario

August 7, 2020

TICAKOREA, PEPCAD NSTEMI, CROSS-AMI, PARTNER-2A 5 years, and more

(The Trials book is supported by Biotronik)

August 5, 2020

Guidance Papers

Guidelines, consensus & position papers

June 25, 2020

Editorial

Intravascular ultrasound in PCI for in-stent CTO: guidance for long-term success

JM De la Torre Hernandez

August 7, 2020

JAA

This Week's JAA's: Real-world Use of the Evolut PRO Valve...